Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions.

Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK.

Eur J Cancer. 2001 Sep;37(14):1797-804.

PMID:
11549434
2.

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

Evans WK, Will BP, Berthelot JM, Wolfson MC.

Can J Oncol. 1995 Dec;5(4):408-19.

PMID:
8770457
3.

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L.

J Natl Cancer Inst. 2000 Aug 16;92(16):1321-9.

4.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

6.

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

Evans WK, Will BP, Berthelot JM, Wolfson MC.

Br J Cancer. 1995 Nov;72(5):1270-7.

7.

Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.

Evans WK, Coyle D, Gafni A, Walker H; National Cancer Institute of Canada Clinical Trials Group--Working Group on Economic Analysis..

Chronic Dis Can. 2003 Fall;24(4):102-7.

PMID:
14733759
8.

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.

Will BP, Le Petit C, Berthelot JM, Tomiak EM, Verma S, Evans WK.

Br J Cancer. 1999 Mar;79(9-10):1428-36.

9.

Economic and cost-effectiveness issues in breast cancer treatment.

Hillner BE.

Semin Oncol. 1996 Feb;23(1 Suppl 2):98-104. Review.

PMID:
8614853
10.

Estimates of the lifetime costs of breast cancer treatment in Canada.

Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK.

Eur J Cancer. 2000 Apr;36(6):724-35.

PMID:
10762744
11.
13.

The benefits and costs of tamoxifen for breast cancer prevention.

Eckermann SD, Martin AJ, Stockler MR, Simes RJ.

Aust N Z J Public Health. 2003;27(1):34-40.

PMID:
14705265
14.

Economic analysis of cancer treatment costs: another tool for oncology managers.

Chirikos TN, Ruckdeschel JC, Krischer JP.

J Oncol Manag. 2001 Jul-Aug;10(3):11-7.

PMID:
11548179
15.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
16.

Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.

Melnikow J, Birch S, Slee C, McCarthy TJ, Helms LJ, Kuppermann M.

Med Care. 2008 Sep;46(9):946-53. doi: 10.1097/MLR.0b013e318179250f.

PMID:
18725849
17.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

18.

Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?

Naeim A, Keeler EB.

Breast Cancer Res Treat. 2005 Nov;94(2):95-103.

PMID:
16261407
19.

Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.

Billingham LJ, Bathers S, Burton A, Bryan S, Cullen MH.

Lung Cancer. 2002 Aug;37(2):219-25.

PMID:
12140146
20.

Cost-effectiveness and lung cancer clinical trials.

Du W, Reeves JH, Gadgeel S, Abrams J, Peters WP.

Cancer. 2003 Oct 1;98(7):1491-6.

Items per page

Supplemental Content

Support Center